Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBIT (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EBIT for 17 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 85.38% to -$5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$387.2 million, a 213.52% decrease, with the full-year FY2025 number at -$387.2 million, down 213.52% from a year prior.
  • EBIT was -$5.7 million for Q4 2025 at Myriad Genetics, up from -$23.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5.7 million in Q4 2025 to a low of -$329.2 million in Q2 2025.
  • A 5-year average of -$55.0 million and a median of -$37.8 million in 2024 define the central range for EBIT.
  • Biggest YoY gain for EBIT was 85.38% in 2025; the steepest drop was 801.92% in 2025.
  • Myriad Genetics' EBIT stood at -$43.1 million in 2021, then decreased by 21.11% to -$52.2 million in 2022, then soared by 39.85% to -$31.4 million in 2023, then decreased by 24.2% to -$39.0 million in 2024, then skyrocketed by 85.38% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBIT are -$5.7 million (Q4 2025), -$23.3 million (Q3 2025), and -$329.2 million (Q2 2025).